Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis
- 1 November 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 9 (6), 509-515
- https://doi.org/10.1097/00063198-200311000-00011
Abstract
Patients with cystic fibrosis are living longer with chronic pulmonary bacterial infections. One consequence of antibiotic treatment of these chronic infections has been the increasing prevalence of antibiotic resistance seen in bacterial isolates recovered from patients with cystic fibrosis. Bacteria such as Pseudomonas aeruginosa and Burkholderia cepacia are able to acquire antibiotic resistance by either spontaneous mutation or gene transfer via plasmids or integrins. In addition, bacteria survive by forming antibiotic-resistant biofilms within the airways of patients with cystic fibrosis. Therapeutic approaches to dealing with antibiotic-resistant bacterial pulmonary infections include the use of in vitro synergy testing to determine optimal double antibiotic combinations or multiple-combination bactericidal testing to determine bactericidal double and triple antibiotic combinations to use against the bacteria in the clinical setting of acute exacerbations. Therapy for antibiotic-resistant bacterial infections in cystic fibrosis involves the use of new laboratory methods (synergy testing or multiple-combination bactericidal testing) to optimize antibiotic treatment strategies. Clinical trials are required to address whether treatment guided by susceptibility testing improves clinical outcomes. Future novel approaches will likely include drugs that can disrupt bacterial biofilm formation and the use of cationic peptide antimicrobial compounds.Keywords
This publication has 64 references indexed in Scilit:
- Tissue Reparative Effects of Macrolide Antibiotics in Chronic Inflammatory Sinopulmonary DiseasesChest, 2003
- Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*Pediatric Pulmonology, 2001
- Technical Report: Precautions Regarding the Use of Aerosolized AntibioticsPediatrics, 2000
- Aminoglycoside‐Resistance Mechanisms for Cystic FibrosisPseudomonas aeruginosaIsolates Are Unchanged by Long‐Term, Intermittent, Inhaled Tobramycin TreatmentThe Journal of Infectious Diseases, 2000
- Quantitation of Inflammatory Responses to Bacteria in Young Cystic Fibrosis and Control PatientsAmerican Journal of Respiratory and Critical Care Medicine, 1999
- In Vitro Activities of Designed Antimicrobial Peptides against Multidrug-Resistant Cystic Fibrosis PathogensAntimicrobial Agents and Chemotherapy, 1999
- Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic FibrosisThe Journal of Infectious Diseases, 1999
- Subepithelial Fibrosis and Degradation of the Bronchial Extracellular Matrix in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Destruction and loss of bronchial cartilage in cystic fibrosisHuman Pathology, 1998
- The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosisPediatric Pulmonology, 1995